Dr. John J. Donnelly, Ph.D. is President of Global Healing, an international NGO that provides training programs for physicians, nurses and laboratory professionals to improve standards of medical care in developing countries with special emphasis on pediatrics and blood safety. He also works as a consultant to vaccine companies, foundations and international organizations. Before joining Global Healing, he directed the Vaccine Development Global Program at PATH, where he also led two vaccine development programs for PATH. The Polio Vaccine Development and Scale-up Program (funded by the Bill and Melinda Gates Foundation) provided technical assistance to developing country manufacturers to expand the global supply of oral polio vaccine (OPV), increase access to affordable inactivated polio vaccine (IPV) and include IPV in affordable pediatric combination vaccines. The Influenza Vaccine Capacity Building Project (funded by US DHHS/ASPR/BARDA) improved capabilities and vaccine quality in manufacturers of influenza vaccine in Brazil, India, China, Serbia and Vietnam. Before joining PATH, Dr. Donnelly worked for more than two decades worked in vaccine R&D for Novartis Vaccines, Chiron, and Merck. He has contributed to several successful vaccine development programs including liquid PedvaxHIB®, Comvax®, New Process Pneumovax®, Menjugate®, Menveo® and Bexsero®. Dr. Donnelly holds a B.A. in Biology and a Ph.D. in Immunology from the University of Pennsylvania, and an M.S. in Strategic Studies from the U.S. Army War College.
Vaccines including polysaccharide-protein conjugate vaccines; Pediatric combination vaccines; Recombinant protein vaccines; Nucleic acid vaccines and live virus vaccines. Protective antigens and mechanisms of resistance in humans against N. meningitidis, H.influenzae, B. pertussis, C. diphtheriae, C. tetani, S. pneumoniae, and S. agalactiae (group B streptococcus). Immunity to viruses including Influenza virus; Respiratory syncytial virus and Poliovirus. Serological methods for defining immunogenicity and efficacy endpoints for vaccines.